U.S. Markets close in 1 hr 51 mins
  • S&P 500

    3,806.52
    -12.31 (-0.32%)
     
  • Dow 30

    30,890.09
    -139.22 (-0.45%)
     
  • Nasdaq

    11,116.47
    -61.42 (-0.55%)
     
  • Russell 2000

    1,719.36
    -0.01 (-0.00%)
     
  • Crude Oil

    106.09
    -3.69 (-3.36%)
     
  • Gold

    1,809.00
    -8.50 (-0.47%)
     
  • Silver

    20.29
    -0.38 (-1.83%)
     
  • EUR/USD

    1.0485
    +0.0042 (+0.3984%)
     
  • 10-Yr Bond

    2.9830
    -0.1100 (-3.56%)
     
  • Vix

    28.58
    +0.42 (+1.49%)
     
  • GBP/USD

    1.2179
    +0.0057 (+0.4713%)
     
  • USD/JPY

    135.6460
    -0.8990 (-0.6584%)
     
  • BTC-USD

    19,119.52
    -966.83 (-4.81%)
     
  • CMC Crypto 200

    410.51
    -20.96 (-4.86%)
     
  • FTSE 100

    7,169.28
    -143.04 (-1.96%)
     
  • Nikkei 225

    26,393.04
    -411.56 (-1.54%)
     

ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
ChemoCentryx, Inc.
ChemoCentryx, Inc.

MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on March 1, 2022 to discuss these results and to answer questions.

To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 3136966. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

About ChemoCentryx
ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the United States, ChemoCentryx markets TAVNEOS® (avacopan), the first approved orally-administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. For more information about the Company visit www.chemocentryx.com.

TAVNEOS® is a registered trademark of ChemoCentryx, Inc. For more information, please see the Full Prescribing Information and Medication Guide, available at TAVNEOS.com.

Contacts
Investors:
Bill Slattery, Jr.
Vice President, Investor Relations
and Corporate Communications
650.210.2970
bslattery@chemocentryx.com

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com